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OBJECTIVE: The aim of this study was to systematically
review published literature about the prevalence, incidence,
and natural history of irritable bowel syndrome (IBS) in
North America.
METHODS: A computer-assisted search of MEDLINE,
EMBASE, and Current Contents/Science Edition databases
was performed independently by two investigators. Study
selection criteria included: 1) North American population-
based sample of adults; 2) objective diagnostic criteria for
IBS (i.e., Rome or Manning criteria); and 3) publication in
full manuscript form in English. Eligible articles were re-
viewed in a duplicate and independent manner. Data ex-
tracted were converted into individual tables and presented
in descriptive form.
RESULTS: The prevalence of IBS in North America ranges
from 3% to 20%, with most prevalence estimates ranging
from 10% to 15%. The prevalences of diarrhea-predominant
and constipation-predominant IBS are both approximately
5%. Published prevalence estimates by gender range from
2:1 female predominance to a ratio of 1:1. Constipation-
predominant IBS is more common in female individuals.
The prevalence of IBS varies minimally with age. No true
population-based incidence studies or natural history studies
were found. In one cohort surveyed on two occasions 1 yr
apart, 9% of subjects who were free of IBS at baseline
reported IBS at follow-up producing an onset rate of 67 per
1000 person-years. In all, 38% of patients meeting criteria
for IBS did not meet IBS criteria at 1-yr follow-up.
CONCLUSION: Approximately 30 million people in North
America meet the diagnostic criteria for IBS. However, data
about the natural history of IBS is quite sparse and renewed
efforts should be focused at developing appropriately de-
signed trials of the epidemiology of IBS. (Am J Gastroen-
terol 2002;97:1910–1915. © 2002 by Am. Coll. of Gastro-
enterology)
INTRODUCTION
Irritable bowel syndrome (IBS) has been defined in the
American Gastroenterological Association medical position
statement as being “a combination of chronic or recurrent GI
symptoms not explained by structural or biochemical ab-
normalities, which is attributed to the intestines and associ-
ated with symptoms of pain and disturbed defecation and/or
symptoms of bloatedness and distention” (1). What makes
IBS so challenging? The etiology is largely unknown, al-
though different mechanisms for its symptoms have been
proposed, including intestinal luminal irritants, psycholog-
ical distress and psychiatric disease, postinfectious or
postinflammatory phenomenon, and abnormal motor func-
tion (2, 3). More recently, abnormal visceral perception has
been proposed as the mechanism behind the pain and ab-
normal defecation patterns (4). Because IBS lacks a “tan-
gible lesion,” IBS has been classified as a functional disor-
der and, as such, has the potential to be trivialized.
However, the relevance of IBS in clinical practice cannot
be questioned. IBS accounts for 25–50% of referrals to
gastroenterologists (5). National health surveys estimate
that each year, there are 3 million physician visits, 2.2
million prescriptions, as well as 96,000 hospital discharges
for IBS (6). One study from Olmsted County, MN, mea-
sured health care use in a random sample of the population
and found that the charges incurred by people with IBS
symptoms were, on average, $300 higher than individuals
without IBS (7). This figure, when extrapolated to the US
population, would represent an excess of 8 billion dollars in
medical costs among IBS patients. Therefore, knowledge of
the epidemiology of IBS is clearly relevant to primary care
providers, gastroenterologists, as well as policy makers.
Our purpose was to perform the first systematic review of
published literature about the epidemiology of IBS in North
America. Our specific study objectives were: 1) to determine the
prevalence of IBS in North America, 2) to characterize the age
of onset and gender distribution of IBS in North America, 3) to
determine the incidence of IBS in North America, and 4) to
characterize the natural history of IBS. Through this systematic
review, limitations of current research may be identified and
recommendations for future research may be suggested.
The opinions and assertions contained herein are solely the views of the authors
and should not be construed as official or as representing the views of the United
States Government or the Department of Veteran Affairs.
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MATERIALS AND METHODS
Literature Search
SEARCH STRATEGY FOR IDENTIFICATION OF
STUDIES. A computer-assisted search of three online bib-
liographic databases was conducted to identify potentially
relevant published papers. A search of the MEDLINE da-
tabase from 1966 to present was performed using medical
subject heading (MeSH) term “colonic diseases, functional”
[mortality, ethnology, epidemiology] or “colonic diseases,
functional” with exploded keywords including “ incidence,”
“prevalence,” “ prognosis,” and “natural history.” Review of
the EMBASE database from 1991 to 2000 was performed
using the following terms: “ [epidemiology],” “ irritable co-
lon,” “ incidence,” “ prevalence,” “ prognosis,” and “history.”
The bibliographic database Current Contents/Science Edi-
tion was also searched between 1996 and 2001 using the
keywords “ irritable bowel syndrome,” “ IBS,” “ colonic dis-
eases, functional,” “ functional colonic diseases,” “ irritable
colon,” “ spastic colon,” “ incidence,” “ prevalence,” “ natural
history,” and “prognosis.” Manual searches of reference
lists from potentially relevant papers were also performed to
identify any additional studies that may have been missed
using the computer-assisted search strategy.
STUDY SELECTION CRITERIA. Two investigators
(Y.S., G.R.L.) independently reviewed the titles and ab-
stracts of all citations identified by the literature search.
Potentially relevant studies were retrieved and the selection
criteria applied. The selection criteria were: 1) studies of
population-based samples of IBS patients derived within
North America; 2) use of Manning, Rome I, or Rome II
criteria to identify IBS patients; 3) population of adult
patients (note that inclusion of pediatric patients within
adult study population was allowed); 4) results reported on
prevalence, incidence, or natural history of IBS; 5) pub-
lished in full manuscript form; and 6) English language
only.
CASE DEFINITION FOR DIAGNOSIS OF IBS. Only
studies defining IBS using the Manning criteria and Rome
criteria were included. The criteria for IBS proposed by
Manning et al. in 1979 (Manning criteria) include the fol-
lowing six symptoms: 1) abdominal pain that is relieved
with a bowel movement, 2) pain associated with looser
stools, 3) pain associated with more frequent stools, 4)
sensation of incomplete evacuation, 5) passage of mucus,
and/or 6) abdominal distention (8). The number of symp-
toms required to meet the diagnosis was not stipulated.
Using a threshold of two was associated with the highest
sensitivity, whereas using a threshold of four was associated
with the highest specificity.
Consensus criteria for the diagnosis of IBS have been
established and subsequently modified by a panel of experts.
The first set of such criteria was developed in conjunction
with a meeting in Rome and, thus, these have become
known as the Rome criteria. The original Rome criteria
(“Rome I” ), as published in 1989, required continuous or
recurrent symptoms of abdominal pain that were 1) relieved
with defecation, 2) associated with a change in frequency of
stool, or 3) associated with a change in consistency of stool
along with two or more symptom groups of disturbed def-
ecation, which included: a) altered stool frequency, b) al-
tered stool form, c) altered stool passage, d) passage of
mucus, and e) usually accompanied by bloating or belief of
abdominal distention (9). These criteria were subsequently
revised and published in 1991 recommending that the pain
be present for at least 3 months, that the symptoms of altered
defecation occur at least 25% of the time, and that symp-
toms from at least three of the above five defecation disorder
symptom groups be present (“modified Rome I” ) (10).
These criteria were recently revised and called the Rome II
criteria (11). Rome II criteria mandate 12 wk of symptoms
in the last year and require that two (rather than just one) of
following features be associated with the pain: a) pain
relieved by bowel movement, b) pain associated with harder
or looser bowel movements, and/or c) pain associated with
more or less frequent bowel movements. The defecation
disorder symptom groups are now only supporting symp-
toms and not required for the diagnosis.
Data Extraction and Data Analysis
Eligible articles were reviewed in a duplicate, independent,
unblinded manner by two investigators (Y.S., G.R.L.).
Agreement between investigators was greater than 95%, and
disagreement in data extraction was resolved by consensus.
For studies about the prevalence of IBS in North America,
the prevalence, incidence, prevalence based on IBS sub-
group, gender distribution, and the mean age of onset were
extracted, if available. For prevalence studies, data about
diagnostic definition of IBS (e.g., Manning criteria, ROME
I criteria), sample size, and case ascertainment techniques to
identify IBS patients (e.g., face-to-face interviews, mail
surveys) was also extracted. For studies about the natural
history of IBS, disease activity (e.g., prevalence of IBS over
time and frequency of IBS flares within a specified period of
time) and frequency of surgery or medication use was ex-
tracted.
Data extracted from original research articles about prev-
alence and gender distribution was converted into individual
tables. The tables are presented in descriptive form. Because
of significant variability in methods of reporting data, no
attempt was made to pool the incidence or prevalence rates,
gender distribution data, age at diagnosis data, or natural
history of disease data.
RESULTS
Characteristics of Selected Studies
Search of the MEDLINE database yielded 232 articles.
Review of the EMBASE database yielded 191 articles.
Searching the Current Contents database yielded 157 arti-
cles with the above-described search. Reviews of the titles
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and abstracts, followed by review of the full manuscripts of
potentially relevant articles, identified eight articles that met
inclusion criteria (12–19). Only studies from the United
States were found, as there were no published population-
based studies from Mexico or Canada.
Prevalence Estimates by Definition
The prevalence estimates for IBS varied between 3% and
20.4% (Table 1), with prevalence rates concentrated at ap-
proximately 10%. In these studies, different definitions of
IBS were used to quantify the prevalence of IBS. In the
National Health Interview Survey (NHIS) performed in
1989, a total of 42,392 individuals were interviewed in a
face-to-face manner to ascertain whether they experienced
symptoms consistent with IBS (12). Using a threshold of
two of six of the Manning symptoms, the US national
prevalence was estimated to be 8% of the population. Using
the modified Rome criteria, the prevalence was estimated to
be 3%. In the US Householder Survey published in 1993,
the investigators surveyed 8250 households selected on the
basis of a stratified probability random sample from a large
consumer opinion mailing list (13). The modified Rome
criteria were used to define cases of IBS. After excluding
those reporting an organic disease, the prevalence for IBS
was 9.4%. Two population-based surveys have been con-
ducted by mail in Olmsted County, MN. In the first study
using a random sample of 1021 residents, 835 (82%) eligi-
ble subjects responded (14). The definition of IBS was
varied using thresholds of two, three, and four or more of the
six Manning symptoms and the presence of frequent recur-
rent abdominal pain. Prevalence estimates after adjustment
to the age and gender structure of the 1990 white population
in the US were 17.0, 12.8, and 8.7 per 100, respectively. In
a follow-up study of this cohort, the prevalence estimates
using Manning and Rome criteria were directly compared
(15). The prevalence per 100 was 20.4 using a threshold of
two Manning symptoms, 15.7 using three symptoms, 8.6
using four symptoms, 13.1 using the original Rome I crite-
ria, and 8.5 using the modified Rome criteria.
Gender Differences in Prevalence
Prevalence estimates for each gender was reported in three
studies (Table 2). The US Householders study found a
higher prevalence in women; the prevalence among the
women in their study was 14.5%, versus 7.7% in men. In the
NHIS, the ratio of female to male individuals with IBS was
also approximately 2:1, although no specific estimates were
given. However, in Olmsted County, the gender-specific





(Response Rate) Case Definition
Prevalence
(per 100)
Hahn et al. NHIS 1989 Face-to-face interviews 42,392 Manning 2 8
Modified Rome I 3
Either criteria 8
Drossman et al. U.S. Householder 1990 Phone interviews 5430/8250 (66%) Modified Rome I 9.4
Talley et al. Olmsted County, MN 1988 Mailed questionnaires 835/1021 (82%) Manning 2p 17.0
Manning 3p 12.8
Manning 4p 8.7
Saito et al. Olmsted County, MN 1992 Mailed questionnaires 643/892 (72%) Manning 2p 20.4
Manning 3p 15.7
Rome I 13.1
Modified Rome I 8.5
Table 2. Prevalence of IBS by Gender
Study Case Definition Prevalence (95% CI)
Drossman et al. (US Householder) Modified Rome I F: 14.5% *
M: 7.7% *
Talley et al. (Olmsted County, MN 1988) Manning 2p F: 18.2 (14.4–21.9)
M: 15.8 (12.2–19.4)
Manning 3p F: 13.6 (10.2–16.9)
M: 12.1 (8.9–15.3)
Saito et al. (Olmsted County, MN 1992) Manning 2p F: 22.4 (17.1–27.7)
M: 18.4 (13.1–23.8)
Manning 3p F: 17.7 (23.9–22.5)
M: 13.5 (8.8–18.3)
Manning 4p F: 10.2 (6.5–13.9)
M: 6.8 (3.1–10.5)
Rome I F: 12.7 (8.6–16.7)
M: 13.3 (8.6–18.1)
Modified Rome I F: 8.4 (5.2–11.7)
M: 8.4 (4.3–12.4)
F  female; M  male.
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prevalence rates have been much more similar between men
and women. In women, the prevalence was 18.2% as com-
pared to 15.8% in males using the Manning 2 criteria, but
the rates were very similar for women and men,12.7% and
13.3%, using the original Rome criteria.
Age and Prevalence
Each of the studies demonstrated slight changes in IBS
prevalence by age. Younger persons had the highest prev-
alence, whereas prevalence was lower in the middle-aged
population. In the US Householders study, the incidence
was 13.5% in the group aged 45 yr compared with 9.4%
in the group aged 45 yr. Similar trends were seen in the
Olmsted County population. However, in a separate study,
a survey was mailed to a cohort of elderly Olmsted County
residents and the prevalence (using three or more Manning
criteria as the definition) increased slightly with age, from
approximately 8% in the group aged 65–74 yr to more than
12% in the group aged 85 yr (16). Overall, these studies
about the prevalence of IBS demonstrate minimal differ-
ences in IBS prevalence based on age. The prevalence of
IBS was approximately 10%, regardless of the age group.
IBS Subgroups
Only one study (17) has looked at the prevalence of IBS by
symptom subgroups (Fig. 1). In a report that used data from
a number of surveys of random samples of Olmsted County
residents, the people who met the Manning criteria for IBS
were further subdivided based on their bowel symptoms.
The overall prevalence of constipation-predominant IBS
was 5.2% and for diarrhea-predominant IBS it was 5.5%.
The prevalence of having both diarrhea and constipation-
type symptoms was 5.2%, whereas 4.2% of participants did
not meet criteria for either constipation or diarrhea. The
age-adjusted, gender-specific prevalence rates were similar
for men and women except in the constipation-predominant
IBS group, in which the prevalence was significantly higher
in women (6.7% vs 3.5%). In the Epidemiology of Consti-
pation study (EPOC), a total of 10,018 persons selected
from across the US were interviewed by telephone (18). The
prevalence for the IBS in the constipation subgroup was
2.1%; the prevalence for those reporting a combination of
IBS and rectal outlet obstruction symptoms was 3.5%.
Incidence of IBS
No true population-based North American IBS incidence
studies were found in this literature search. A single study
used repeated surveys over time to estimate incidence (19).
In Olmsted County, a cohort was surveyed on two occasions
1 yr apart, using the Manning criteria, and 9% of subjects
free of IBS at baseline reported IBS in follow-up. This was
calculated to be an onset rate of 67 per 1000 person-years.
However, this study did not determine whether study pa-
tients had a past medical history of IBS. These surveys,
which report the development of IBS symptoms over the
course of 1 yr, determine only whether the study patients
had active IBS at the onset of the study. Thus, these respon-
dents may not have been true “ incident” cases with first-time
onset of symptoms.
Natural History
The same study, which used repeated surveys over a 1-yr
interval, evaluated natural history of IBS and met inclusion
criteria for this systematic review. In this longitudinal study
done in Olmsted County, 38% of subjects who met the
definition of IBS (using two or more Manning criteria) did
not meet the criteria at 1-yr follow-up. Over 1 year, the
prevalence using the Manning criteria changed only from
17% to 18.1%. Using the modified Rome criteria, the prev-
alence changed from 7.2% to 8.0%. Thus, there is a relative
numerical balance in the number of persons who begin to
meet and fail to meet the definition of IBS over time. No
other study of North American IBS patients provides data
about other aspects of natural history. Thus, no study in this
systematic review provides data about disease activity of
IBS or about frequency of surgery or medication use.
DISCUSSION
Our systematic review of the literature has shown that the
prevalence estimates for IBS in the United States have
ranged from 3% to 20%; however, this wide range of prev-
alence estimates seems to be the result of changes in the
definition of IBS used rather than true differences in IBS
prevalence. No one definition can be considered a gold
standard for the diagnosis, although the hope is that Rome
II will become such. Unfortunately, the studies in this re-
view were performed before the development of the Rome
II criteria. Nevertheless, most estimates indicate that the
prevalence of IBS is approximately 10–15%, and this esti-
mate is consistent with multiple non-US IBS studies sum-
marized in previous review articles (20). An IBS prevalence
of 10–15% estimates that as many as 30–45 million North
American adults have symptoms of IBS during any given
year. Yet, this systematic review is marked by the sparse
data about the natural history of IBS in North America,
Figure 1. Age-adjusted prevalence of IBS (per 100 subjects) by
symptom subgroups in Olmsted County, MN, 1988–1993. a-ibs 
both constipation and diarrhea; c-ibs  constipation-predominant;
d-ibs  diarrhea-predominant; n-ibs  neither constipation nor
diarrhea.
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including the incidence of IBS, disease activity or frequency
of surgery, and medication use. Given the relative lack of
data, this systematic review reinforces the need for appro-
priately designed trials to clarify the epidemiology of IBS.
This review has shown fairly consistent results in the
prevalence estimates by age, gender, and symptom sub-
group. The prevalence decreases slightly with age in most
trials, and the prevalence is similar for constipation-predom-
inant IBS and diarrhea-predominant IBS. Unlike clinic-
based studies (21), population-based studies do not demon-
strate the 4:1 female to male predominance. Rather, in the
community, this ratio ranges from 1:1 to 2:1. The underlying
reasons behind these gender differences are unclear. They
could, again, be related to criteria used for diagnosis (15); or
they could be related to sociocultural differences, differ-
ences in health-care seeking behavior between men and
women, or true biological differences in the natural history
of IBS between men and women. Future epidemiological
research should seek to elicit possible reasons underlying
these findings.
Appropriately designed trials about the incidence of IBS
in North America are lacking. One population-based study
has been reported by one of the authors (G.L.) but presented
only in abstract form (22). The incidence of a clinical
diagnosis of IBS was determined in Olmsted County by
identifying persons with a diagnosis of IBS in the medical
record, and reviewing their medical records to be sure that
the person had not received a diagnosis of IBS in the
preceding decade. The incidence was found to be 200 per
100,000 person-years, although this estimate is likely to be
lower than the true incidence of IBS for reasons discussed
below.
Optimal natural history studies would provide data about
the disease activity of IBS, frequency of surgery and med-
ication use, or even the frequency that IBS symptoms cause
these individuals to miss work. Although no studies that met
our prespecified criteria provided this information, other
sources do provide some estimates about the natural history
of IBS. IBS is an episodic disorder, marked by periods of
severe disease activity followed by periods of minimal
symptoms. A single study has examined the natural history
of IBS symptoms during a period of severe IBS disease
activity (23). In this study, 122 IBS patients in the United
Kingdom who actively sought care for symptomatic IBS
were followed for 12 wk. The study patients reported ap-
proximately 12 distinct “episodes” of IBS symptoms over
the 12-wk period. Maximum duration of each IBS episode
was 5 days, although the majority of study patients reported
IBS symptoms on more than 50% of days. Thus, in this trial
in the United Kingdom, patients alternate between several
days with symptoms and several days without symptoms.
The results from the single IBS natural history trial (includ-
ing those in this systematic review) demonstrated that up to
38% of IBS patients did not meet diagnostic criteria for IBS,
and reported prolonged symptom-free periods after 1 yr of
follow-up, suggesting that IBS patients may develop a “ re-
mission” after a series of symptomatic episodes (19). Lon-
gitudinal studies have also been done outside the US, and
one study in particular bears reporting (24). A Swedish team
surveyed individuals on two occasions 1 yr apart, and found
symptom onset and disappearance rates similar to those in
the previous study in Olmsted County, MN. This study went
a step further by showing that the symptoms changed over
time. The 40% of individuals who were said to have “dis-
appearance” of IBS symptoms actually had other GI symp-
toms during follow-up, and the 10% who had “onset” of IBS
often had other symptoms at baseline. Thus, the coming and
going of symptoms is not an all-or-none phenomenon;
rather, there is a great deal of symptom change.
Data about the frequency of surgery or medication use or
even the frequency of missed work because of IBS symp-
toms are also part of the natural history of IBS, although no
population-based trials of North American patients report
these data in full manuscript form. Nevertheless, prescrip-
tion databases suggest that a low estimate of the cost of
pharmaceutical use by IBS patients exceeds 80 million
dollars annually, with total costs of health care exceeding 1
billion dollars annually (25). The US Householder Survey
(13) estimated that IBS patients miss 13 days of work
annually because of illness, compared with control patients
who miss only 5 days of work annually because of illness.
If the additional work loss resulting from illness is attrib-
utable to IBS, then the indirect costs from this absenteeism
may exceed 19 billion annually (25). Finally, additional
indirect data suggests that IBS patients are more likely to
undergo abdominal surgical procedures. Specifically, one
population-based trial in the United Kingdom found that
cholecystectomy was more common in IBS patients com-
pared with controls (4.6% vs 2.4%, respectively; p  0.01;
OR  1.9, 95% CI  1.2–3.2) (26). IBS patients are more
likely to undergo hysterectomy (27) and appendectomy (28)
compared with controls. Finally, based on recent abstract
data, the lifetime prevalence of abdominal surgery in IBS
patients may be two times higher when compared with
normal controls (59% vs 32%, respectively) (29).
Given the paucity of literature about the incidence and
natural history of IBS, renewed efforts should focus on the
development of well-designed trials about the epidemiology
of this disease. These trials will need to overcome several
potential pitfalls. First, in the prevalence studies, only 50%
of people with IBS symptoms report having ever seen a
physician for these symptoms; thus, medical records cannot
identify everyone with IBS. Symptoms may come and go;
thus, symptom inventories must be taken repeatedly over
time. Recent studies have identified that IBS symptoms are
common in both middle school and high school aged indi-
viduals (30). Thus, a true IBS incidence study would require
data collection to begin almost at birth. Therefore, optimal
trials about the epidemiology of IBS would meet the fol-
lowing criteria for a natural history study: 1) population-
based samples of patients followed from the time of diag-
nosis, 2) appropriate and objective criteria for the initial
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diagnosis of disease, and 3) sufficiently long and complete
follow-up of the cohort of patients using objective defini-
tions of disease activity and other outcomes (31). Appro-
priate trial outcomes may include assessment of disease
activity, medication use, health care resource use, frequency
of surgery, and frequency of absenteeism from work be-
cause of IBS symptoms.
Thus, there is clearly need for a prospective cohort study
to determine the exact incidence and natural history of IBS.
Ideally, this study should be community based, with at least
an annual survey collecting information regarding the pres-
ence of symptoms and their severity and frequency, as well
as collecting information regarding morbidity, mortality,
and health care use. Otherwise, quantifying the natural his-
tory of symptoms in a prospective manner will be impossi-
ble. These studies and others suggest that the health care
burden of IBS is great in the US population. Further inves-
tigation of the true health and financial burden of IBS should
be performed.
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